These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 16265875)
1. Obstacles and opportunities in the clinical development of targeted therapeutics. Dy GK; Adjei AA Prog Drug Res; 2005; 63():19-41. PubMed ID: 16265875 [No Abstract] [Full Text] [Related]
2. Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous. Markman M Cancer; 2010 Nov; 116(22):5116-8. PubMed ID: 20665504 [No Abstract] [Full Text] [Related]
3. Next generation oncology drug development: opportunities and challenges. Gutierrez ME; Kummar S; Giaccone G Nat Rev Clin Oncol; 2009 May; 6(5):259-65. PubMed ID: 19390552 [TBL] [Abstract][Full Text] [Related]
4. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy? Bell IM J Med Chem; 2004 Apr; 47(8):1869-78. PubMed ID: 15055985 [No Abstract] [Full Text] [Related]
5. Developmental therapeutics in childhood cancer. A perspective from the Children's Oncology Group and the US Food and Drug Administration. Bernstein ML; Reaman GH; Hirschfeld S Hematol Oncol Clin North Am; 2001 Aug; 15(4):631-55. PubMed ID: 11676277 [TBL] [Abstract][Full Text] [Related]
6. Treatment of elderly patients with antineoplastic chemotherapy. Tirelli U; Monfardini S J Clin Oncol; 1995 May; 13(5):1282-3. PubMed ID: 7738634 [No Abstract] [Full Text] [Related]
16. Medical oncology in the 1990s. Braverman AS Lancet; 1991 Apr; 337(8746):901-2. PubMed ID: 1672980 [No Abstract] [Full Text] [Related]
17. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities. Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382 [TBL] [Abstract][Full Text] [Related]
18. Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. Mailankody S; Prasad V Oncologist; 2016 Sep; 21(9):1031-2. PubMed ID: 27401893 [TBL] [Abstract][Full Text] [Related]
19. Using "rationally designed drugs" rationally. Brugarolas J; Clark JW; Chabner B Lancet; 2003 May; 361(9371):1758-9. PubMed ID: 12781531 [No Abstract] [Full Text] [Related]
20. [Clinical evaluation of glyciphosphoramide used alone and in combination with other drugs]. Wang ZY Zhonghua Zhong Liu Za Zhi; 1984 Sep; 6(5):379-81. PubMed ID: 6398774 [No Abstract] [Full Text] [Related] [Next] [New Search]